We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Axcan Pharma (MM) | NASDAQ:AXCA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 23.34 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of January, 2008
Commission File Number 0-30860
Axcan Pharma Inc.
(Exact Name of Registrant)
597, boul, Laurier, Mont-Saint-Hilaire (Québec), Canada J3H 6C4
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F o Form 40-F x
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7):
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also hereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No x
If Yes is marked, indicate the file number assigned to the registrant in connection with Rule 12g3-2(b):
82-
EXHIBITS
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
January 14, 2008 Letter to Shareholders of Axcan Pharma Inc.. |
|
|
|
|
|
99.2 |
|
December 20, 2007 press release entitled Axcan Pharma Inc. Obtains Interim Order for Proposed Arrangement and Announces Date of Special Shareholder Meeting. |
|
|
|
|
|
99.3 |
|
January 10, 2008 press release entitled Axcan and TPG Capital Receive Antitrust Clearances in Connection with the Proposed Acquisition. |
|
|
|
|
|
99.4 |
|
January 10, 2008 press release entitled ISS, Proxy Governance, Inc. and Glass, Lewis & Co. Recommend Shareholders Vote For the Proposed Acquisition of Axcan Pharma by an Affiliate of TPG Capital. |
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
AXCAN PHARMA INC. |
Date: January 14, 2008 |
By: |
/s/ Richard Tarte |
|
Name: |
Richard Tarte |
|
Title: |
Vice President, Corporate Development |
|
|
and General Counsel |
3
1 Year Axcan Pharma (MM) Chart |
1 Month Axcan Pharma (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions